Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
ImpactNotable 35/100
Why it mattersRule-based estimate: event keywords (+6); trust 7/10.
RegionsGlobal
Published3 h ago (Mon, 21 Sep 2026 16:59:16 GMT)
RetrievedMon, 21 Sep 2026 17:00:53 GMT via rss
ClassifiedMon, 21 Sep 2026 18:01:24 GMT by heuristic